Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.

Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.

The present invention is directed to various compounds, compositions, and methods for treating bacterial infections such as urinary tract infections.

The present invention is directed to various compounds, compositions, and methods for treating bacterial infections such as urinary tract infections.

Embodiments of the invention include a novel synthesis of the translocator protein (TSPO) ligands, and methods of imaging a molecular events. Also disclosed are compounds for treatment of diseases, including cancer.

Embodiments of the invention include a novel synthesis of the translocator protein (TSPO) ligands, and methods of imaging a molecular events. Also disclosed are compounds for treatment of diseases, including cancer.

Cyphomycin, an isolated compound of Formula I or IA is provided. A compound isolated from insect Streptomyces and having a chemical formula of C.sub.77H.sub.122O.sub.26 is also provided. Compositions including Cyphomycin, such as pharmaceutical compositions including effective amounts of Cyphomycin for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with Cyphomycin and compositions thereof are disclosed.

Cyphomycin, an isolated compound of Formula I or IA is provided. A compound isolated from insect Streptomyces and having a chemical formula of C.sub.77H.sub.122O.sub.26 is also provided. Compositions including Cyphomycin, such as pharmaceutical compositions including effective amounts of Cyphomycin for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with Cyphomycin and compositions thereof are disclosed.

The present disclosure relates to the field of pharmacology, and in particular, to a preparation method of high-purity total ginkgo flavonol glycoside. The preparation method of high-purity total ginkgo flavonol glycoside includes: (1) mixing Ginkgo biloba extract powder and a first alkaline solution, subjecting to dissolution and centrifugation to obtain a supernatant; (2) subjecting the supernatant to separation with an acid-polar coupled macroporous resin column and to purification with a polyamide column, to obtain high-purity total ginkgo flavonol glycoside. The purity of the total ginkgo flavonol glycoside prepared by the preparation method of high-purity total ginkgo flavonol glycoside according to the present disclosure is 90%, and has good clinical application prospects; the preparation process does not require organic reagents such as petroleum ether and ethyl acetate, which is environmentally friendly; the transfer rate of the total flavonol glycoside is high.

The present disclosure relates to the field of pharmacology, and in particular, to a preparation method of high-purity total ginkgo flavonol glycoside. The preparation method of high-purity total ginkgo flavonol glycoside includes: (1) mixing Ginkgo biloba extract powder and a first alkaline solution, subjecting to dissolution and centrifugation to obtain a supernatant; (2) subjecting the supernatant to separation with an acid-polar coupled macroporous resin column and to purification with a polyamide column, to obtain high-purity total ginkgo flavonol glycoside. The purity of the total ginkgo flavonol glycoside prepared by the preparation method of high-purity total ginkgo flavonol glycoside according to the present disclosure is 90%, and has good clinical application prospects; the preparation process does not require organic reagents such as petroleum ether and ethyl acetate, which is environmentally friendly; the transfer rate of the total flavonol glycoside is high.